Key Takeaways
- • KKR & Co. Inc., through affiliate Tarheel Investors III L.P., holds a 14.0% stake in Integer Holdings Corporation (NYSE: ITGR), reportable after equity swaps settled on Oct. 5, 2026.
- • The stake was disclosed in a Schedule 13D filed Oct. 13, 2026, alongside a definitive merger agreement signed Aug. 2, 2026 for KKR affiliates to acquire Integer.
- • Integer shareholders will receive $127 per share in cash at closing, a transaction valued at approximately $5.7 billion according to the announcement.
- • Tarheel settled physically settled swaps for 4,753,677 shares and holds a cash-settled swap tied to 836,392 shares that carries no voting rights.
- • A KKR affiliate has committed equity to fund the merger consideration and provided a limited guarantee covering certain obligations of the acquisition vehicle; closing remains subject to customary conditions, including stockholder and regulatory approvals.
Summary
KKR & Co. Inc. has acquired a 14.0% economic and beneficial position in Integer Holdings Corporation, a Plano, Texas-based medical device contract development and manufacturing organization, according to a Schedule 13D filed with the SEC on Oct. 13, 2026. The position was acquired through Tarheel Investors III L.P., a KKR affiliate, after equity swaps settled on Oct. 5, 2026, which triggered the reporting obligation.
The disclosed stake is closely tied to a take-private transaction. KKR affiliates agreed to acquire Integer under a definitive merger agreement signed Aug. 2, 2026. Under the terms, each outstanding share of common stock will be converted into the right to receive $127 in cash at the effective time, subject to customary closing conditions. The announcement values the transaction at approximately $5.7 billion and represents a premium of approximately 51.8% to Integer's pre-announcement share price, per the publisher's transaction disclosure.
According to the filing, Tarheel settled physically settled swaps to acquire 4,753,677 shares. It also holds a cash-settled swap referencing 836,392 shares, which confers no voting rights. To finance the transaction, a KKR affiliate has committed to invest the equity required to enable the acquisition vehicle to pay the merger consideration, and has provided a limited guarantee covering certain obligations of that vehicle.
KKR, a Delaware corporation and global investment firm with private equity, credit, and real assets strategies, has a track record in large-scale buyouts across healthcare and medical technology. The transaction is expected to be completed as a take-private, removing Integer from public markets upon closing. Completion remains subject to stockholder approval and regulatory clearances.
The disclosed stake is closely tied to a take-private transaction. KKR affiliates agreed to acquire Integer under a definitive merger agreement signed Aug. 2, 2026. Under the terms, each outstanding share of common stock will be converted into the right to receive $127 in cash at the effective time, subject to customary closing conditions. The announcement values the transaction at approximately $5.7 billion and represents a premium of approximately 51.8% to Integer's pre-announcement share price, per the publisher's transaction disclosure.
According to the filing, Tarheel settled physically settled swaps to acquire 4,753,677 shares. It also holds a cash-settled swap referencing 836,392 shares, which confers no voting rights. To finance the transaction, a KKR affiliate has committed to invest the equity required to enable the acquisition vehicle to pay the merger consideration, and has provided a limited guarantee covering certain obligations of that vehicle.
KKR, a Delaware corporation and global investment firm with private equity, credit, and real assets strategies, has a track record in large-scale buyouts across healthcare and medical technology. The transaction is expected to be completed as a take-private, removing Integer from public markets upon closing. Completion remains subject to stockholder approval and regulatory clearances.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.